Survodutide

📦 Elke bestelling is gedekt door onze Reshipment Assurance Policy — als uw pakket niet binnen 20 werkdagen arriveert, sturen wij het opnieuw.

What Is Survodutide?

Survodutide (developmental code BI 456906) is a long-acting dual GLP-1 and glucagon receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It represents the Western pharmaceutical arm of the dual GLP-1/glucagon co-agonist research programme, alongside the parallel programmes that produced mazdutide (Innovent Biologics, China) and the older Pegapamodutide / Cotadutide compounds. Survodutide is structurally compact — just 29 amino acids — substantially shorter than the oxyntomodulin-derived dual agonists, while preserving balanced agonist activity at both target receptors through engineered substitutions and fatty-acid acylation.

Survodutide has a mature molecular weight of approximately 3,800 Da including the acyl modification. The 29-residue length is one of the structural distinctives: shorter peptides are typically cheaper to synthesise per unit dose but have less surface area for fine-tuning receptor-balance pharmacology. Boehringer-Zealand achieved the dual-agonist balance through a combination of strategic Aib substitutions at DPP-4 cleavage sites and careful tuning of receptor-binding-pocket residues. Plasma half-life is approximately 6 days, supporting once-weekly subcutaneous dosing.

The current clinical signature of survodutide is the striking MASH (metabolic-dysfunction-associated steatohepatitis) liver-fibrosis effect reported in the Phase 2 trial — an outcome that distinguished it from other dual and triple agonists with similar body-weight effects. Phase 2 obesity data showed body-weight reductions of approximately 19% at 4.8 mg weekly over 46 weeks, putting survodutide in the same effect-size tier as tirzepatide and at the boundary of triple-agonist retatrutide. Survodutide is currently in Phase 3 trials for obesity (SURMOUNT-style trial design) and MASH. Survodutide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The research-grade survodutide sold here is supplied uitsluitend voor laboratoriumonderzoek and is not intended for human or veterinary administration. For the sibling dual GLP-1/glucagon co-agonist, see our Mazdutide product page; for the triple-agonist that adds GIP, see Retatrutide.

Mechanism of Action — Dual GLP-1 / Glucagon Receptor Co-Agonism with Hepatic Emphasis

What makes survodutide mechanistically distinctive among dual-agonist metabolic peptides is the relatively balanced GLP-1-to-glucagon potency ratio that produces both substantial energy-expenditure effects (the glucagon arm) and the canonical GLP-1 satiety/glycaemic effects, with a particular emphasis on hepatic outcomes:

• GLP-1 receptor activation — satiety, β-cell insulin secretion, gastric emptying — Survodutide activates the GLP-1 receptor on pancreatic beta-cells (glucose-dependent insulin secretion, glucagon suppression from alpha-cells), hypothalamic arcuate-nucleus POMC neurons (central appetite regulation), and gastric vagal afferents (delayed gastric emptying). This arm overlaps with semaglutide’s mechanism and the GLP-1 component of all multi-agonist incretin peptides.
• Glucagon receptor activation — hepatic lipid mobilisation, energy expenditure, brown adipose activation — The defining feature shared with mazdutide en retatrutide is glucagon-receptor agonism. In survodutide research, this arm produces particularly strong hepatic lipid mobilisation — hepatocytes are highly enriched for glucagon receptors, and direct glucagon-pathway activation drives fatty-acid oxidation and triglyceride export. The combined effect with the GLP-1 arm’s indirect liver benefits via reduced insulin resistance produces the distinctive MASH-fibrosis signal observed in Phase 2.
• Receptor-balance engineering and the dual-agonist potency ratio — The pharmacological challenge in dual GLP-1/glucagon co-agonism is achieving the right relative potency at each receptor. Glucagon agonism alone raises glucose; GLP-1 agonism alone produces strong glucose-lowering. The net effect depends on the in-vivo ratio of receptor occupancy at each site. Survodutide is engineered for a glucagon-favoured balance relative to mazdutide, which contributes to the stronger hepatic effects but requires more careful titration to avoid net glucose effects in early dose-escalation research protocols.

The fatty-acid acylation at a lysine residue (analogous in concept to semaglutide’s C18 acyl chain) drives reversible serum-albumin binding that produces the ~6-day plasma half-life and supports once-weekly subcutaneous dosing in clinical research. Subcutaneous administration is the standard research route and the only route used in clinical development.

Published Research Applications

Survodutide is used in laboratory research contexts that investigate:

• MASLD/MASH (metabolic-dysfunction-associated liver disease) — hepatic triglyceride content, ALT/AST normalisation, fibrosis-stage progression in preclinical models and clinical Phase 2 data; survodutide’s strongest research signal and the basis for its dedicated MASH Phase 3 programme
• Obesity and body-composition research — preclinical DIO rodent models, body-composition (DEXA/MRI), food-intake assays, energy-expenditure measurement
• Type 2 diabetes preclinical research — glycaemic control, glucagon-suppression dynamics, HbA1c surrogates; the engineered receptor-balance favours net glucose-lowering despite the glucagon component
• Energy-expenditure and thermogenesis research — resting energy expenditure, brown adipose tissue activation, thermogenic gene expression; particularly relevant given the glucagon arm
• Comparative dual-agonist research — head-to-head with the alternative dual GLP-1/glucagon co-agonist Mazdutide (oxyntomodulin-derived, 39 aa), the dual GLP-1/GIP Tirzepatide, and the triple-agonist Retatrutide; receptor-stacking strategy research
• Cardiovascular research — effects on blood pressure, lipid profiles; cardiovascular outcome data accumulating from Phase 2/3 programmes
• Glucagon-axis pharmacology — isolated glucagon-receptor pharmacology, hepatic glucose-output dynamics, glucagon vs GLP-1 receptor potency balance characterisation
• Comparative incretin research — benchmarking against single-agonist GLP-1 (Semaglutide) and amylin-axis combination pharmacology (Cagrilintide + Semaglutide CagriSema).

For broader context on where survodutide fits within the multi-agonist metabolic-peptide landscape, see Mazdutide as the sibling dual GLP-1/glucagon co-agonist, Retatrutide as the triple-agonist that adds GIP, Tirzepatide as the alternative dual using GIP instead of glucagon, and Semaglutide as the single-agonist baseline. Browse the full onderzoekspeptiden catalogus voor gerelateerde verbindingen.

Beschikbare sterktes en concentraties

MedsBase stocks Survodutide in two lyophilized vial sizes calibrated to typical research protocol lengths. Each strength is available in 10-vial or 20-vial pack formats with full reconstitution guidance:

Both strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Phase 2 clinical doses are 0.3–4.8 mg weekly with a 4–6 month titration schedule, so research-grade vials at 5 mg or 10 mg represent multi-week supplies of clinical-equivalent dosing for in-vivo work. Survodutide is a comparatively scarce research peptide because of active clinical development and Western-pharmaceutical supply-chain controls, which is reflected in the per-mg price relative to mature small synthetic peptides.

How It Compares — Survodutide vs Mazdutide

Survodutide and Mazdutide are the two principal dual GLP-1 / glucagon co-agonist research peptides in current literature. They share receptor pharmacology — both activate the GLP-1 and glucagon receptors, both lack GIP activity — but differ in structural origin, length, and engineered receptor-balance ratio. The comparison is one of the cleanest in current dual-agonist pharmacology because the receptor targets are identical and only the molecular implementation differs.

For MASH/MASLD liver-disease research, survodutide is the more frequently cited dual-agonist tool because of its distinctive Phase 2 hepatic-fibrosis signal. For research interested in the glycaemic axis with minimal glucagon-pathway interference, mazdutide’s GLP-1-favoured balance is the cleaner choice. The two peptides together represent the principal Western (Boehringer-Zealand) and Eastern (Innovent) approaches to dual GLP-1/glucagon co-agonist pharmacology — both are likely to remain in active research and clinical development through this decade.

Opslag en Reconstituering

Voor reconstituering: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. Lyophilized survodutide is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder.

Reconstitueringsprocedure: inject bacteriostatic water down the side wall of the vial (not directly onto the lyophilized cake). For a 5 mg vial, 2.0 mL of bacteriostatic water yields a 2.5 mg/mL working concentration — 0.04 mL delivers 100 mcg; 0.2 mL delivers 500 mcg; ~1.9 mL delivers a 4.8 mg clinical-equivalent research dose. Swirl gently — do niet shake — and allow 5–10 minutes for full dissolution (acylated peptides dissolve more slowly than smaller unmodified peptides). A correctly reconstituted solution should be clear and colourless with no visible particles.

Na reconstitutie: store refrigerated at 2–8 °C and use within 30 days for optimal stability. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration.

Veelgestelde vragen

What is Survodutide used for in research?

Survodutide is used in laboratory research investigating MASLD/MASH liver disease (its strongest distinctive research signal), obesity and body-composition regulation, type 2 diabetes preclinical models, energy-expenditure and thermogenesis, and comparative multi-agonist incretin pharmacology against single-agonist GLP-1, dual GLP-1/GIP (tirzepatide), the sibling dual GLP-1/glucagon mazdutide, and triple-agonist retatrutide. The research-grade survodutide sold here is niet FDA-approved and is supplied strictly for laboratory research use only.

How is Survodutide different from Mazdutide?

Both are dual GLP-1/glucagon co-agonists with the same receptor targets, but they differ in structural origin and engineered receptor-balance ratio. Survodutide is a compact 29-amino-acid Boehringer-Zealand compound with a glucagon-favoured potency balance that produces particularly strong hepatic effects (the basis for its Phase 2 MASH signal). Mazdutide is a ~39-amino-acid oxyntomodulin-derived Innovent compound with a GLP-1-favoured balance that produces cleaner glycaemic effects. For MASH research, survodutide is the canonical choice; for clean glycaemic-axis research with minimal glucagon interference, mazdutide is preferred.

How is Survodutide different from Tirzepatide?

Both are dual incretin agonists, but they activate different second receptors. Tirzepatide is GLP-1 + GIP (~22% body-weight effect in SURMOUNT-1). Survodutide is GLP-1 + glucagon (~19% in Phase 2). The two receptor combinations produce qualitatively different metabolic profiles: GIP adds adipocyte lipolysis under fasting conditions; glucagon adds substantial energy expenditure and hepatic lipid mobilisation. Survodutide has the unique MASH-fibrosis signal because of its glucagon-driven hepatic lipid effect.

How is Survodutide different from Retatrutide?

Retatrutide adds GIP receptor activation on top of GLP-1 + glucagon — it is a triple agonist. Survodutide stops at the dual combination. Retatrutide’s Phase 2 body-weight effect (~24%) is larger than survodutide’s (~19%), suggesting GIP adds substantial benefit. Survodutide has the stronger MASH signal in its respective Phase 2 trial. For research isolating the dual GLP-1 + glucagon combination without the GIP confound, survodutide (and mazdutide) are the cleaner tools.

What is the typical Survodutide research dose?

Published Phase 2 clinical protocols use weekly subcutaneous dosing with a long titration schedule starting at 0.3 mg and stepping through 0.9, 1.8, 2.4, 3.6 to a maintenance dose of 4.8 mg weekly over approximately 24 weeks. A 5 mg vial reconstituted with 2.0 mL bacteriostatic water yields 2.5 mg/mL — ~1.9 mL equals a 4.8 mg clinical-equivalent research dose.

Is Survodutide FDA approved?

No. Survodutide is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. Phase 3 trials for obesity and MASH are ongoing as of current literature. All survodutide sold by research-use-only suppliers is for laboratory investigation and should not be administered to humans.

How should Survodutide be stored?

Lyophilized vials: refrigerated at 2–8 °C for short-term working stock, or −20 °C for long-term storage of unopened vials. Reconstituted solution: refrigerated at 2–8 °C, use within 30 days. Do not freeze reconstituted solution — freeze-thaw cycles degrade the peptide. Protect from direct light at all times.

How do I reconstitute Survodutide?

Follow the reconstitution procedure above. Add bacteriostatic water down the side wall of the vial (not onto the lyophilized cake), swirl gently, and allow 5–10 minutes for full dissolution (acylated peptides dissolve more slowly than smaller unmodified peptides). Do niet shake the vial. A correctly reconstituted solution is clear and colourless. For a 5 mg vial + 2.0 mL diluent, the working concentration is 2.5 mg/mL.

Welke sterktes heeft MedsBase op voorraad?

MedsBase carries Survodutide in 5 mg and 10 mg lyophilized vials. Each strength is available in 10-vial or 20-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.

Why is Survodutide particularly relevant for MASH research?

Survodutide’s glucagon-favoured dual-receptor balance produces especially strong hepatic effects in published research. Hepatocytes are highly enriched for glucagon receptors, so glucagon-pathway activation directly drives fatty-acid oxidation and triglyceride export from steatotic liver. Combined with the GLP-1 arm’s indirect benefits via reduced insulin resistance, the dual effect on the liver translates into the striking MASH-fibrosis-stage improvement reported in the Phase 2 trial — an outcome that distinguished survodutide from other dual and triple agonists at comparable body-weight effects.

Does the glucagon component cause hyperglycaemia?

The classic “glucagon paradox” applies to survodutide as it does to other dual GLP-1/glucagon co-agonists: glucagon alone raises glucose by stimulating hepatic glucose output, but the GLP-1 component’s dominant glucose-lowering action on insulin and glucagon-suppression at beta- and alpha-cells overrides this. Survodutide’s engineered receptor-balance ratio achieves net glucose-lowering despite glucagon receptor activation — published Phase 2 data confirms improved glycaemic control in T2DM cohorts at maintenance dose.

Does Survodutide cause side effects in research?

The most consistent finding is gastrointestinal, similar to other GLP-1-axis peptides — nausea, transient appetite suppression, and delayed gastric emptying are dose-dependent and tend to attenuate with the long titration schedule used in Phase 2. Glucagon-component-related findings include modest elevations in resting heart rate and (rarely) transient blood-pressure effects. The long titration is partly designed to minimise these effects.

What is the half-life of Survodutide?

In preclinical and clinical research, survodutide has a plasma half-life of approximately 6 days following subcutaneous administration, comparable to tirzepatide (~5 days) and slightly shorter than semaglutide (~7 days). The half-life is achieved by reversible binding to circulating serum albumin via the fatty-acid acyl tether at a lysine residue.

How long does Survodutide take to show effects in preclinical research?

Acute pharmacodynamic effects on glucose tolerance and gastric emptying are detectable within hours of the first dose. Body-weight effects in DIO rodent models typically become statistically significant after 1–2 weeks of weekly dosing. MASLD/MASH effects on hepatic triglyceride content and ALT/AST normalisation accumulate over 8–16 weeks of regular dosing. Maximum body-composition effect develops over 24–46 weeks, mirroring the Phase 2 trajectory.

Can I order Survodutide for international shipping?

Yes. MedsBase ships Survodutide worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our Reshipment Assurance Policy.

Other Peptides for Metabolic, MASH, and Multi-Agonist Research

• Mazdutide — Sibling dual GLP-1/glucagon co-agonist — alternative receptor-balance ratio
• Retatrutide — Triple GLP-1/GIP/glucagon agonist — adds GIP to the dual GLP-1/glucagon profile
• Tirzepatide — Dual GLP-1/GIP agonist — alternative dual-agonist using GIP instead of glucagon
• Semaglutide — Single GLP-1 agonist — canonical baseline comparator
• Cagrilintide — Amylin analog — alternative combination-pharmacology approach

Verder lezen

Meer opties in Peptiden

Gerangschikt op recente bestelvolumes van MedsBase — wat andere klanten in deze categorie kiezen.

BPC-157

US$115.00 – US$705.00Preisspanne: US$115.00 bis US$705.00

Retatrutide

US$310.00 – US$6,515.00Preisspanne: US$310.00 bis US$6,515.00

BAC Water (Bacteriostatisch Water)

US$50.00 – US$150.00Preisspanne: US$50.00 bis US$150.00

NAD⁺

US$210.00 – US$1,975.00Preisspanne: US$210.00 bis US$1,975.00